Related Experiment Video
Updated: Jul 31, 2026
09:38
Generalized Psychophysiological Interaction (PPI) Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease
Published on: November 14, 2017
Increased risk for ischaemic events is related to combined RAS polymorphism
P P van Geel1, Y M Pinto, A H Zwinderman
1Department of Cardiology, University of Groningen, Antonius Deusinglaan 1, 9713 AV Groningen, Netherlands. p.p.geel@med.rug.nl
Heart (British Cardiac Society)
|March 17, 2001
Summary
Patients with both ACE-DD and AT(1)R-CC genotypes had more ischaemic events. This increased risk of cardiovascular events was not linked to coronary atherosclerosis progression.
Area of Science:
- Cardiovascular Genetics
- Pharmacogenomics
- Coronary Artery Disease Research
Background:
- The renin-angiotensin system plays a crucial role in cardiovascular regulation.
- Gene polymorphisms in the angiotensin converting enzyme (ACE) and angiotensin II type 1 receptor (AT(1)R) are associated with cardiovascular disease risk.
- Investigating gene-gene interactions can elucidate complex disease pathways.
Purpose of the Study:
- To investigate the combined effect of ACE (rs4343) and AT(1)R (A1166C) gene polymorphisms on ischaemic event risk.
- To determine if this interaction influences the progression of coronary atherosclerosis.
Main Methods:
- Prospective substudy of the REGRESS trial involving 885 male patients with stable coronary artery disease.
- Two-year follow-up assessing ischaemic events.
- Serial quantitative coronary arteriography to measure coronary atherosclerosis progression (mean segment diameter, minimum obstruction diameter).
Main Results:
- Patients with the ACE-DD and AT(1)R-CC genotypes exhibited a significantly higher incidence of ischaemic events (p = 0.035).
- No significant association was found between these genotypes and the progression of coronary atherosclerosis (mean segment diameter or minimum obstruction diameter) at baseline or after two years.
Conclusions:
- The ACE-DD and AT(1)R-CC genotypes interact to increase the risk of ischaemic events.
- This heightened risk is not explained by accelerated progression of angiographically defined coronary atherosclerosis.
Related Concept Videos
02:38The Ras Gene
The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a superfamily...
Ras is a superfamily...
01:11Genome-wide Association Studies-GWAS
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
GWAS does not require the identification of the target gene involved in...
01:24Small GTPases - Ras and Rho
Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity:
Three regulatory proteins control their activity:
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:30Coronary Artery Disease I: Introduction
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...